ForePass Endoscopic Device Matches Bariatric Surgery Results, Outperforms Semaglutide 8:1 in Preclinical Study

Keyron announced publication in Gut (Impact Factor 26.2) demonstrating that its ForePass endoscopic metabolic bypass platform — an incision-free, fully reversible procedure — reproduced insulin sensitivity levels comparable to biliopancreatic diversion (BPD), the most powerful and invasive bariatric surgery.

Key Results (Large-Animal Randomized Preclinical Study)

• Insulin sensitivity: matched BPD-level effects, more than 2-fold higher than semaglutide
• Weight control: ForePass limited weight gain by 4.3% vs. 36% for semaglutide (8-fold outperformance) and 4.3% vs. 47% for controls (10-fold)
• Glucose regulation: near-complete suppression of postprandial glucose excursions with substantially reduced insulin demand

Clinical Context

• BPD achieves ~80% diabetes remission and 40–50% total body weight loss in humans — but only ~1% of eligible patients undergo it due to invasiveness
• 92% of semaglutide patients fail to achieve even 15% weight loss (NEJM 2021)
• ForePass is designed as a short outpatient endoscopic procedure — positioning it as a middle ground between drugs and surgery

Strategic Implications

• ForePass advances toward first-in-human clinical studies targeting severe obesity and metabolic disease
• If successful in humans, represents a device-based competitor to GLP-1 drugs for patients with advanced metabolic disease, potentially without lifelong drug dependency
• Could disrupt both the bariatric surgery market (Intuitive Surgical, Medtronic) and capture patients for whom GLP-1s are insufficient